Kling BiotherapeuticsKling Biotherapeutics
The company is headquartered in Amsterdam, Netherlands with a fully owned IP portfolio that covers platform technologies Kling-Select and Kling-Evolve for the simultaneous discovery of novel targets and identification of fully human antibodies directly from patient-derived B cells.
Kling-Select relies on a fully-owned and clinically-validated B cell immortalization technology to identify novel therapeutic targets and antibody binders from patients with exceptional clinical responses. This technology has successfully identified novel neutralizing antibodies for various infectious diseases such as RSV (nirsevimab/Beyfortus™; on market and estimated to be a billion dollar plus product), Covid, and Influenza. More recently, Kling-Select has been applied to peripheral and tumor-infiltrating B cells derived from cancer patients and produced a portfolio of novel and selective target-antibody pairs. The unbiased nature of this discovery platform allows identification of novel targets and unique epitopes inaccessible to traditional target discovery approaches. Kling-Evolve enables the ex vivo affinity maturation of B cell clones against targets of interest. This powerful technology can be used for the rapid evolution of neutralizing antibodies against emerging viral variants or for affinity and selectivity improvement of oncology assets. Kling Biotherapeutics is progressing a unique pipeline of oncology programs with KBA1412, a first-in-class CD9 antibody, being tested in a Phase 1 clinical trial.
Kling is led by a globally experienced leadership team with an established track record in the field antibody based therapeutics.
Michael KoslowskiCEO
Stefano GullaCSO
Tim WrightChairman, General Partner at Time BioVentures
D. A. WallachDirector, General Partner at Time BioVenturesMichael KoslowskiCEO
Alessandra Micaela VillaDirector Platform Development
Arjen BakkerSenior Scientist
Bas PietersProtein Scientist
Bella MonicaSenior Research Associate
Casper MarsmanScientist, B Cell Platform Lead
Esmay FrankinSenior Research Associate
Gea van LaarExecutive Assistant & Office Manager
Jurgen HeinenSenior Research Associate
Kelly MaijoorAssociate Scientist
Martijn KeddePrincipal Scientist, Biology and Protein Sciences Lead
Peter HollemanDirector Clinical Operations
Remko SchotteSenior Scientist, Biomarkers and Translational Medicine Lead
Rob RooversDirector Preclinical Development
Sebastian BaumannProtein Scientist
Vanessa Clerico MosinaProtein ScientistIn a career spanning academic research, clinical medicine, big pharma, and biotech, Dr. Wright has guided the development of twenty breakthrough drugs now on the market, including 10 “blockbusters” that have each sold over $1 billion USD annually. He brings to Time BioVentures’ portfolio deep expertise in translational science and commercialization, as well as an understanding of the dynamics of the private and public biotech markets.
Dr. Wright began his career as a physician-scientist, completing his medical degree, rheumatology clinical fellowship, and post-docs in molecular biology and immunology at Johns Hopkins University. He subsequently served on the faculty at Hopkins, and then as a tenured Associate Professor and Division Chief at the University of Pittsburgh School of Medicine, where he ran an NIH-funded research laboratory.
Following a successful leap from academia to industry, Dr. Wright spent three years at Pfizer in Research and Exploratory Development. He then moved to Novartis Pharmaceuticals where he held roles of increasing responsibility, including Deputy Head of Translational Research, Global Head of Translational Medicine, Global Head of Translational Sciences, and finally, Global Head of Pharma Development.
In 2015, Dr. Wright moved to California and immersed himself in the fast-paced world of start-up biotech, first as Executive Vice President at CALIBR (affiliated with Scripps Research), and then as Chief R&D officer at Regulus Therapeutics. Dr. Wright serves as a scientific advisor to the Bill and Melinda Gates Foundation and the Leonard Schaeffer Center for Health Policy and Economics at USC. He has also held Board of Directors roles at Schrodinger and CureVac, two prominent public biotech companies.